Season 4

Jan. 27, 2023

A Game-Changing Year for Biosimilars

This year, six biosimilars for the top-selling medicine, Humira, will enter the market, with the first launching on January 31, 2023. Increased competition from biosimilars can drive down costs. But experts argue that insurer...

Episode page
Jan. 20, 2023

What Congress Can Do for Patients in 2023

Can a divided Congress work together to help patients? Health policy experts Jon Deuser and Mike Gaffin tackle that question. They explain what health care issues Congress might address, including the lack of transparency aro...

Episode page
Jan. 13, 2023

Accelerating Access to New Treatments

A new Alzheimer’s treatment received FDA approval under the accelerated approval program. Former FDA Associate Commissioner Peter Pitts explains how the accelerated approval pathway leads to incremental innovation, or buildin...

Episode page
Jan. 6, 2023

New Year, New Health Care Changes

Last year President Biden signed the Inflation Reduction Act into law, which included several changes to Medicare. Terry and Dr. Bob discuss the three changes that start this year, including the $35 monthly cap on insulin, an...

Episode page